Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy

Joeri A. Jansweijer, Karin Nieuwhof, Francesco Russo, Edgar T. Hoorntje, Jan D.H. Jongbloed, Ronald H. Lekanne Deprez, Alex V. Postma, Marieke Bronk, Ingrid A.W. van Rijsingen, Simone de Haij, Elena Biagini, Paul L. van Haelst, Jan van Wijngaarden, Maarten P. van den Berg, Arthur A.M. Wilde, Marcel M.A.M. Mannens, Rudolf A. de Boer, Karin Y. van Spaendonck-Zwarts, J. Peter van Tintelen, Yigal M. Pinto

Research output: Contribution to journalArticleAcademicpeer-review

115 Citations (Scopus)

Abstract

Aims: Truncating titin mutations (tTTN) occur in 25% of dilated cardiomyopathy (DCM) cases, but the phenotype and severity of disease they cause have not yet been systematically studied. We studied whether tTTN variants are associated with a clinically distinguishable form of DCM. Methods and results: We compared clinical data on DCM probands and relatives with a tTTN mutation (n = 45, n = 73), LMNA mutation (n = 28, n = 29), and probands who tested negative for both genes [idiopathic DCM (iDCM); n = 60]. Median follow-up was at least 2.5 years in each group. TTN subjects presented with DCM at higher age than LMNA subjects (probands 47.9 vs. 40.4 years, P = 0.004; relatives 59.8 vs. 47.0 years, P = 0.01), less often developed LVEF <35% [probands hazard ratio (HR) 0.38, P = 0.002], had higher age of death (probands 70.4 vs. 59.4 years, P < 0.001; relatives 74.1 vs. 58.4 years, P = 0.008), and had better composite outcome (malignant ventricular arrhythmia, heart transplantation, or death; probands HR 0.09, P < 0.001; relatives HR 0.21, P = 0.02) than LMNA subjects and iDCM subjects (HR 0.36, P = 0.07). An LVEF increase of at least 10% occurred in 46.9% of TTN subjects after initiation of standard heart failure treatment, while this only occurred in 6.5% of LMNA subjects (P < 0.001) and 18.5% of iDCM subjects (P = 0.02). This was confirmed in families with co-segregation, in which the 10% point LVEF increase occurred in 55.6% of subjects (P = 0.003 vs. LMNA, P = 0.079 vs. iDCM). Conclusions: This study shows that tTTN-associated DCM is less severe at presentation and more amenable to standard therapy than LMNA mutation-induced DCM or iDCM.

Original languageEnglish
Pages (from-to)512-521
Number of pages10
JournalEuropean journal of heart failure
Volume19
Issue number4
Early online date2016
DOIs
Publication statusPublished - 1 Apr 2017

Keywords

  • Diagnosis
  • Dilated cardiomyopathy
  • Gene
  • Prognosis
  • Treatment

Cite this